Line Plot from Scientific Research

β-Glucan-polymersomes, as a monotherapy or combined with anti-PD-1 checkpoint inhibition, were administered intravenously to B16F10 melanoma-bearing C57BL/6 mice and tumour growth was monitored for 8 days. The tumour growth profiles show that β-glucan-polymersome immunotherapy effectively inhibited tumour growth as a monotherapy and in combination with anti-PD-1 checkpoint therapy, n = 10 per group.

DOI